Cargando…
‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others
Several large clinical trials are underway to discover therapies to delay or prevent the onset of dementia caused by Alzheimer’s disease (AD). A common feature of these trials is that they are testing therapies in people who do not yet have changes in memory or thinking—that is, who are cognitively...
Autores principales: | Largent, Emily A, Stites, Shana D, Harkins, Kristin, Karlawish, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132957/ https://www.ncbi.nlm.nih.gov/pubmed/34040780 http://dx.doi.org/10.1093/jlb/lsab004 |
Ejemplares similares
-
Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer’s Disease
por: Stites, Shana D., et al.
Publicado: (2021) -
How Biomarker-Based Diagnosis and Treatment Affect Alzheimer’s Stigma: Results of a Randomized Trial
por: Stites, Shana, et al.
Publicado: (2021) -
Gender Differences in How the American Public Reacts to a Person With Mild-Stage Dementia
por: Stites, Shana, et al.
Publicado: (2020) -
What is paradoxical lucidity? The answer begins with its definition
por: Peterson, Andrew, et al.
Publicado: (2021) -
IS THERE A DIFFERENCE BETWEEN TERMINAL LUCIDITY AND PARADOXICAL LUCIDITY?
por: Peterson, Andrew, et al.
Publicado: (2022)